Estela Ayala Meyer, MD
Pulmonary Disease · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Offices
- 2
Offices
2 locations · Physician Services at El Camino Hospital · Sutter Bay Medical Foundation
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Meyer’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A92908 · Current
Licensed to practise in California · since 2005 · expires 2027-08-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$154,583
Medicare paid this office $154,583 for 394 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 199 | $48,240 | $113 |
| Critical care, first 30-74 minutes | 104 | $45,939 | $184 |
| Long return visit (40+ min) | 82 | $21,548 | $166 |
| New patient visit (45+ min) | 48 | $7,195 | $150 |
| Test to examine how well the lungs exchange gases | 101 | $6,336 | $59 |
See all 15 services
| Return visit (30+ min) | 199 | $48,240 | $113 |
| Critical care, first 30-74 minutes | 104 | $45,939 | $184 |
| Long return visit (40+ min) | 82 | $21,548 | $166 |
| New patient visit (45+ min) | 48 | $7,195 | $150 |
| Test to examine how well the lungs exchange gases | 101 | $6,336 | $59 |
| Test to determine lung volumes using sensors | 100 | $6,207 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 85 | $3,307 | $38 |
| New patient visit (60+ min) | 12 | $2,517 | $210 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,766 | $68 |
| Critical care, each additional 30 minutes | 13 | $1,591 | $94 |
| Short return visit (20+ min) | 12 | $1,418 | $89 |
| Influenza vaccine, inactivated | 13 | $1,064 | $82 |
| Test to measure expiratory airflow and volume | 22 | $748 | $29 |
| Administration of influenza virus vaccine | 14 | $547 | $39 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 26 | $436 | $15 |
Who their Medicare patients are
394 Original Medicare patients in 2024. Average age 79 · Women 59% · Also on Medicaid 16% · Health risk score 1.93. At or below the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · COPD 49% · Coronary heart disease 40% · Diabetes 34% · Chronic kidney disease 33% · Atrial fibrillation 32% · Heart failure 30% · Depression 23% · Cancer 20% · Dementia 13% · Stroke 12%.
The office billed $652,643, Medicare allowed $201,520 and paid $154,583; for 1,404 services of 38 kinds; $2,016 of it was for drugs given in the office and $152,567 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 394 | 1,404 | 79 | 1.93 | $652,643 | $154,583 |
| 2023 | 406 | 1,259 | 78 | 1.92 | $581,426 | $139,891 |
| 2022 | 409 | 1,421 | 78 | 2.02 | $619,745 | $161,299 |
| 2021 | 398 | 1,345 | 78 | 1.69 | $524,137 | $146,966 |
| 2020 | 390 | 1,302 | 77 | 1.89 | $495,299 | $134,736 |
| 2019 | 476 | 1,876 | 77 | 2.06 | $594,040 | $157,949 |
| 2018 | 437 | 1,612 | 77 | 1.87 | $546,937 | $138,267 |
| 2017 | 422 | 1,628 | 76 | 1.92 | $514,647 | $137,802 |
| 2016 | 460 | 1,525 | 76 | 1.91 | $492,532 | $126,416 |
| 2015 | 405 | 1,491 | 76 | 1.86 | $491,361 | $137,857 |
| 2014 | 294 | 1,099 | 75 | 1.71 | $416,745 | $104,359 |
| 2013 | 311 | 1,338 | 74 | 1.42 | $323,246 | $84,514 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Critical care, first 30-74 minutes | 106 | $45,710 | $189 |
| Return visit (30+ min) | 199 | $44,017 | $112 |
| Long return visit (40+ min) | 63 | $13,548 | $167 |
| New patient visit (45+ min) | 46 | $6,800 | $148 |
| Test to examine how well the lungs exchange gases | 79 | $5,355 | $61 |
| Test to determine lung volumes using sensors | 77 | $4,901 | $58 |
| Short return visit (20+ min) | 29 | $3,025 | $78 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 67 | $2,729 | $39 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,605 | $73 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 12 | $1,473 | $123 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,058 | $76 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $813 | $43 |
| Test to measure expiratory airflow and volume | 20 | $659 | $27 |
| Test to determine lung volumes using sensors | 15 | $160 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 13 | $119 | $9 |
| Test to examine how well the lungs exchange gases | 15 | $119 | $8 |
2022: 14 services
| Critical care, first 30-74 minutes | 101 | $54,098 | $197 |
| Return visit (30+ min) | 210 | $53,677 | $116 |
| Long return visit (40+ min) | 60 | $13,562 | $172 |
| New patient visit (45+ min) | 45 | $6,465 | $144 |
| Short return visit (20+ min) | 52 | $5,432 | $86 |
| Test to examine how well the lungs exchange gases | 79 | $5,296 | $62 |
| Test to determine lung volumes using sensors | 78 | $4,895 | $58 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 70 | $2,890 | $40 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 20 | $1,405 | $70 |
| Test to measure expiratory airflow and volume | 26 | $824 | $27 |
| Administration of influenza virus vaccine | 21 | $794 | $38 |
| Test to determine lung volumes using sensors | 15 | $153 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $150 | $9 |
| Test to examine how well the lungs exchange gases | 16 | $121 | $8 |
2021: 14 services
| Return visit (30+ min) | 205 | $50,101 | $121 |
| Critical care, first 30-74 minutes | 79 | $37,249 | $202 |
| Long return visit (40+ min) | 69 | $14,467 | $170 |
| Short return visit (20+ min) | 75 | $8,113 | $84 |
| New patient visit (45+ min) | 48 | $7,507 | $156 |
| Test to examine how well the lungs exchange gases | 79 | $5,417 | $61 |
| Test to determine lung volumes using sensors | 80 | $5,159 | $57 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 67 | $3,085 | $45 |
| Influenza vaccine split virus, preservative free | 21 | $1,370 | $65 |
| Test to measure expiratory airflow and volume | 28 | $1,139 | $31 |
| Administration of influenza virus vaccine | 23 | $503 | $22 |
| Test to determine lung volumes using sensors | 16 | $179 | $11 |
| Test to examine how well the lungs exchange gases | 17 | $140 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $134 | $10 |
2020: 18 services
| Critical care, first 30-74 minutes | 110 | $55,145 | $203 |
| Return visit (30+ min) | 173 | $33,059 | $99 |
| New patient visit (45+ min) | 48 | $6,700 | $140 |
| Short return visit (20+ min) | 50 | $5,207 | $74 |
| Long return visit (40+ min) | 21 | $4,682 | $156 |
| Telephone medical discussion with physician, 11-20 minutes | 40 | $3,704 | $79 |
| Test to examine how well the lungs exchange gases | 57 | $3,539 | $56 |
| Test to determine lung volumes using sensors | 57 | $3,470 | $55 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 52 | $3,376 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,506 | $64 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,300 | $108 |
| Influenza vaccine split virus, preservative free | 16 | $954 | $60 |
| Test to measure expiratory airflow and volume | 15 | $608 | $32 |
| Administration of influenza virus vaccine | 18 | $375 | $21 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | $242 | $12 |
| Test to determine lung volumes using sensors | 18 | $194 | $11 |
| Test to examine how well the lungs exchange gases | 19 | $151 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 16 | $2 | None |
2019: 17 services
| Return visit (30+ min) | 250 | $56,798 | $99 |
| Critical care, first 30-74 minutes | 105 | $47,789 | $196 |
| New patient visit (45+ min) | 95 | $14,120 | $149 |
| Test to examine how well the lungs exchange gases | 108 | $6,856 | $57 |
| Test to determine lung volumes using sensors | 106 | $6,520 | $55 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 92 | $5,819 | $61 |
| Long return visit (40+ min) | 30 | $4,314 | $139 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,121 | $64 |
| Short return visit (20+ min) | 25 | $1,942 | $72 |
| Test to measure expiratory airflow and volume | 29 | $1,204 | $33 |
| Influenza vaccine split virus, preservative free | 17 | $916 | $54 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $713 | $36 |
| Administration of influenza virus vaccine | 17 | $349 | $21 |
| Test to determine lung volumes using sensors | 24 | $267 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 22 | $260 | $11 |
| Test to examine how well the lungs exchange gases | 24 | $197 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 90 | $9 | None |
2018: 19 services
| Critical care, first 30-74 minutes | 115 | $47,896 | $192 |
| Return visit (30+ min) | 214 | $41,630 | $93 |
| New patient visit (45+ min) | 78 | $11,547 | $148 |
| Test to examine how well the lungs exchange gases | 83 | $5,337 | $56 |
| Test to determine lung volumes using sensors | 83 | $5,266 | $56 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 67 | $4,400 | $63 |
| Short return visit (20+ min) | 39 | $3,608 | $68 |
| Long return visit (40+ min) | 26 | $2,920 | $108 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,589 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,388 | $58 |
| Test to measure expiratory airflow and volume | 31 | $1,382 | $36 |
| New patient visit (30+ min) | 12 | $1,219 | $102 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,041 | $33 |
| Influenza vaccine split virus, preservative free | 13 | $566 | $44 |
| Administration of influenza virus vaccine | 15 | $386 | $26 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 23 | $316 | $12 |
| Test to determine lung volumes using sensors | 23 | $295 | $11 |
| Test to examine how well the lungs exchange gases | 22 | $213 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 58 | $7 | None |
2017: 18 services
| Critical care, first 30-74 minutes | 100 | $43,678 | $195 |
| Return visit (30+ min) | 190 | $43,015 | $96 |
| New patient visit (45+ min) | 100 | $14,399 | $144 |
| Test to examine how well the lungs exchange gases | 78 | $4,895 | $55 |
| Test to determine lung volumes using sensors | 78 | $4,784 | $54 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 70 | $4,270 | $60 |
| Long return visit (40+ min) | 32 | $4,196 | $123 |
| Short return visit (20+ min) | 28 | $2,242 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,570 | $63 |
| New patient visit (30+ min) | 14 | $1,230 | $88 |
| Test to measure expiratory airflow and volume | 26 | $1,159 | $36 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $1,013 | $34 |
| Influenza vaccine split virus, preservative free | 16 | $699 | $44 |
| Administration of influenza virus vaccine | 17 | $547 | $32 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 37 | $463 | $11 |
| Test to determine lung volumes using sensors | 35 | $411 | $11 |
| Test to examine how well the lungs exchange gases | 35 | $303 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 61 | $7 | None |
2016: 19 services
| Critical care, first 30-74 minutes | 122 | $47,267 | $190 |
| Return visit (30+ min) | 222 | $36,094 | $88 |
| New patient visit (45+ min) | 65 | $9,296 | $143 |
| Test to examine how well the lungs exchange gases | 95 | $5,170 | $50 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 83 | $4,578 | $55 |
| Test to determine lung volumes using sensors | 57 | $3,211 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $3,105 | $61 |
| Long return visit (40+ min) | 19 | $2,319 | $116 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,065 | $121 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $1,685 | $34 |
| Test to determine lung volumes using gas dilution or washout | 36 | $1,350 | $36 |
| Influenza vaccine split virus, preservative free | 35 | $1,290 | $37 |
| Test to measure expiratory airflow and volume | 27 | $1,139 | $34 |
| Administration of influenza virus vaccine | 35 | $1,009 | $29 |
| Test to determine lung volumes using sensors | 16 | $177 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 14 | $165 | $12 |
| Test to examine how well the lungs exchange gases | 16 | $131 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 44 | $5 | None |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 11 | $2 | None |
2015: 15 services
| Return visit (30+ min) | 199 | $48,158 | $94 |
| Critical care, first 30-74 minutes | 97 | $33,569 | $205 |
| New patient visit (45+ min) | 98 | $15,090 | $154 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 96 | $6,405 | $62 |
| Test to examine how well the lungs exchange gases | 87 | $5,429 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,278 | $68 |
| Test to determine lung volumes using sensors | 82 | $5,064 | $55 |
| Long return visit (40+ min) | 27 | $3,962 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,164 | $120 |
| Short return visit (20+ min) | 28 | $2,015 | $69 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 12 | $1,340 | $112 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $1,269 | $36 |
| Test to measure expiratory airflow and volume | 17 | $707 | $35 |
| Administration of influenza virus vaccine | 14 | $440 | $31 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 32 | $4 | None |
2014: 14 services
| Return visit (30+ min) | 151 | $38,681 | $88 |
| Critical care, first 30-74 minutes | 74 | $26,388 | $195 |
| New patient visit (45+ min) | 64 | $8,989 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $5,700 | $64 |
| Long return visit (40+ min) | 30 | $4,870 | $132 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 48 | $2,737 | $55 |
| Test to examine how well the lungs exchange gases | 47 | $2,524 | $49 |
| Test to determine lung volumes using sensors | 46 | $2,487 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,465 | $117 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 12 | $1,208 | $101 |
| Short return visit (20+ min) | 18 | $1,054 | $55 |
| Test to measure expiratory airflow and volume | 15 | $544 | $32 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $510 | $34 |
| Administration of influenza virus vaccine | 11 | $334 | $30 |
2013: 18 services
| Return visit (30+ min) | 196 | $41,539 | $83 |
| Test to examine how well the lungs exchange gases | 128 | $7,284 | $52 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 133 | $7,256 | $53 |
| New patient visit (45+ min) | 55 | $7,011 | $127 |
| Test to determine lung volumes using sensors | 107 | $5,860 | $51 |
| Long return visit (40+ min) | 27 | $3,817 | $116 |
| Short return visit (20+ min) | 39 | $2,655 | $56 |
| New patient visit (30+ min) | 15 | $1,182 | $79 |
| Test to determine lung volumes using gas dilution or washout | 20 | $841 | $40 |
| Test to measure expiratory airflow and volume | 14 | $661 | $31 |
| Administration of influenza virus vaccine | 19 | $577 | $30 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 19 | $354 | $19 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 18 | $76 | $4 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 55 | $6 | None |
| Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | 24 | $4 | None |
| Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 13 | $2 | None |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 13 | $2 | None |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 21 | $2 | None |
Medicaid work
$3,198 in 2022
Medicaid paid $3,198 for 40 billed services this clinician did in 2022, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 40 | $3,198 |
| 2022 | 40 | 1 | 14 | $3,198 |
| 2021 | 39 | 1 | 12 | $6,901 |
See the largest Medicaid services in earlier years
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 39 | $6,901 |
Drugs they prescribed that Part D paid
$1,143,945
Pharmacies billed $1,143,945 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,782) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
0 generic and 1,252 brand-name prescriptions · $1,143,945 in drug cost · 85 antibiotic prescriptions to 47 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 32 | $423,159 | $13,224 |
| Trelegy Ellipta | 426 | $352,207 | $827 |
| Breo Ellipta | 132 | $69,310 | $525 |
| Anoro Ellipta | 82 | $46,459 | $567 |
| Spiriva Respimat | 58 | $40,609 | $700 |
See all 29 drugs
| Ofev | 32 | $423,159 | $13,224 |
| Trelegy Ellipta | 426 | $352,207 | $827 |
| Breo Ellipta | 132 | $69,310 | $525 |
| Anoro Ellipta | 82 | $46,459 | $567 |
| Spiriva Respimat | 58 | $40,609 | $700 |
| Incruse Ellipta | 82 | $37,183 | $453 |
| Spiriva Handihaler | 30 | $24,048 | $802 |
| Breztri Aerosphere | 20 | $19,876 | $994 |
| Arnuity Ellipta | 49 | $12,383 | $253 |
| Advair Hfa | 21 | $12,341 | $588 |
| Symbicort | 24 | $9,784 | $408 |
| Bevespi Aerosphere | 23 | $8,888 | $386 |
| Stiolto Respimat | 11 | $7,605 | $691 |
| Atrovent Hfa | 16 | $7,402 | $463 |
| Dulera | 17 | $6,697 | $394 |
| Wixela Inhub | 63 | $6,525 | $104 |
| Albuterol Sulfate Hfa | 191 | $5,931 | $31 |
| Fluticasone-Salmeterol | 20 | $3,899 | $195 |
| Breyna | 13 | $2,509 | $193 |
| Ventolin Hfa | 22 | $2,055 | $93 |
| Mycophenolate Mofetil | 34 | $2,025 | $60 |
| Budesonide-Formoterol | 12 | $1,859 | $155 |
| Ipratropium | 18 | $1,562 | $87 |
| Azelastine | 19 | $903 | $48 |
| Montelukast | 62 | $813 | $13 |
| Mycophenolic Acid | 15 | $507 | $34 |
| Prednisone | 76 | $438 | $6 |
| Doxycycline Hyclate | 25 | $311 | $12 |
| Azithromycin | 37 | $166 | $4 |
Year by year
| 2024 | 1,782 | 244 | 0% (0) | 70% | $1,143,945 |
| 2023 | 1,472 | 219 | 0% (0) | 71% | $786,937 |
| 2022 | 1,174 | 203 | 0% (0) | 65% | $531,101 |
| 2021 | 1,283 | 202 | 0% (0) | 67% | $621,863 |
| 2020 | 1,319 | 210 | 0% (0) | 70% | $526,734 |
| 2019 | 1,605 | 237 | 0% (0) | 73% | $688,717 |
| 2018 | 1,599 | 219 | 0% (0) | 76% | $725,320 |
| 2017 | 1,467 | 227 | 0% (0) | 75% | $506,622 |
| 2016 | 1,114 | 205 | 0% (0) | 72% | $379,758 |
| 2015 | 1,244 | 175 | None | 66% | $374,749 |
| 2014 | 1,030 | 159 | None | 71% | $324,338 |
| 2013 | 1,125 | 184 | None | 70% | $315,557 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 25 drugs
| Trelegy Ellipta | 322 | $270,885 | $841 |
| Breo Ellipta | 124 | $74,884 | $604 |
| Anoro Ellipta | 80 | $48,109 | $601 |
| Symbicort | 57 | $40,829 | $716 |
| Spiriva Handihaler | 31 | $37,580 | $1,212 |
| Spiriva Respimat | 42 | $31,934 | $760 |
| Incruse Ellipta | 54 | $30,889 | $572 |
| Breztri Aerosphere | 25 | $17,938 | $718 |
| Flovent Hfa | 33 | $15,669 | $475 |
| Advair Diskus | 26 | $14,470 | $557 |
| Arnuity Ellipta | 35 | $9,534 | $272 |
| Albuterol Sulfate Hfa | 153 | $5,841 | $38 |
| Dulera | 16 | $5,643 | $353 |
| Wixela Inhub | 18 | $5,127 | $285 |
| Roflumilast | 16 | $3,587 | $224 |
| Ventolin Hfa | 35 | $2,793 | $80 |
| Levalbuterol Tartrate Hfa | 20 | $1,377 | $69 |
| Mycophenolic Acid | 11 | $956 | $87 |
| Montelukast | 64 | $927 | $14 |
| Azelastine | 15 | $675 | $45 |
| Prednisone | 69 | $360 | $5 |
| Azithromycin | 35 | $208 | $6 |
| Doxycycline Hyclate | 15 | $194 | $13 |
| Amoxicillin-Clavulanate Potass | 11 | $149 | $14 |
| Famotidine | 24 | $142 | $6 |
2022: 24 drugs
| Trelegy Ellipta | 197 | $147,117 | $747 |
| Anoro Ellipta | 78 | $55,100 | $706 |
| Spiriva Handihaler | 57 | $50,882 | $893 |
| Breo Ellipta | 70 | $40,094 | $573 |
| Incruse Ellipta | 58 | $30,699 | $529 |
| Symbicort | 53 | $28,111 | $530 |
| Spiriva Respimat | 19 | $10,911 | $574 |
| Breztri Aerosphere | 16 | $10,314 | $645 |
| Daliresp | 16 | $9,883 | $618 |
| Wixela Inhub | 46 | $9,708 | $211 |
| Flovent Hfa | 15 | $7,177 | $478 |
| Dulera | 18 | $6,079 | $338 |
| Arnuity Ellipta | 22 | $5,477 | $249 |
| Albuterol Sulfate Hfa | 99 | $5,108 | $52 |
| Mycophenolic Acid | 15 | $1,625 | $108 |
| Montelukast | 55 | $1,089 | $20 |
| Levalbuterol Tartrate Hfa | 18 | $1,037 | $58 |
| Azelastine | 18 | $918 | $51 |
| Prednisone | 83 | $501 | $6 |
| Fluticasone Propionate | 16 | $413 | $26 |
| Doxycycline Hyclate | 11 | $203 | $18 |
| Azithromycin | 26 | $172 | $7 |
| Gabapentin | 11 | $126 | $11 |
| Famotidine | 11 | $81 | $7 |
2021: 23 drugs
| Trelegy Ellipta | 131 | $88,971 | $679 |
| Breo Ellipta | 122 | $69,159 | $567 |
| Spiriva | 81 | $65,902 | $814 |
| Incruse Ellipta | 94 | $43,408 | $462 |
| Anoro Ellipta | 82 | $42,220 | $515 |
| Symbicort | 56 | $31,115 | $556 |
| Spiriva Respimat | 33 | $21,898 | $664 |
| Stiolto Respimat | 12 | $10,538 | $878 |
| Daliresp | 13 | $8,865 | $682 |
| Flovent Hfa | 14 | $7,903 | $565 |
| Wixela Inhub | 21 | $7,850 | $374 |
| Dulera | 21 | $6,536 | $311 |
| Albuterol Sulfate Hfa | 104 | $6,529 | $63 |
| Arnuity Ellipta | 20 | $4,320 | $216 |
| Azelastine | 46 | $1,851 | $40 |
| Levalbuterol Tartrate Hfa | 25 | $1,827 | $73 |
| Mycophenolate Mofetil | 13 | $1,145 | $88 |
| Ventolin Hfa | 16 | $942 | $59 |
| Montelukast | 75 | $829 | $11 |
| Prednisone | 108 | $718 | $7 |
| Fluticasone Propionate | 23 | $566 | $25 |
| Nystatin | 11 | $267 | $24 |
| Azithromycin | 20 | $145 | $7 |
2020: 22 drugs
| Breo Ellipta | 209 | $97,103 | $465 |
| Spiriva | 102 | $71,153 | $698 |
| Anoro Ellipta | 96 | $53,468 | $557 |
| Incruse Ellipta | 103 | $48,127 | $467 |
| Symbicort | 80 | $43,046 | $538 |
| Trelegy Ellipta | 24 | $22,807 | $950 |
| Spiriva Respimat | 37 | $21,106 | $570 |
| Flovent Hfa | 33 | $16,119 | $488 |
| Advair Hfa | 15 | $11,917 | $794 |
| Wixela Inhub | 40 | $11,785 | $295 |
| Advair Diskus | 16 | $8,711 | $544 |
| Dulera | 20 | $7,464 | $373 |
| Arnuity Ellipta | 17 | $4,265 | $251 |
| Albuterol Sulfate Hfa | 64 | $3,889 | $61 |
| Ventolin Hfa | 35 | $2,379 | $68 |
| Proair Hfa | 13 | $2,132 | $164 |
| Azelastine | 32 | $1,691 | $53 |
| Montelukast | 98 | $1,238 | $13 |
| Prednisone | 110 | $751 | $7 |
| Ipratropium | 12 | $628 | $52 |
| Fluticasone Propionate | 16 | $409 | $26 |
| Azithromycin | 26 | $164 | $6 |
2019: 28 drugs
| Ofev | 11 | $114,876 | $10,443 |
| Breo Ellipta | 243 | $111,973 | $461 |
| Spiriva | 159 | $107,079 | $673 |
| Anoro Ellipta | 121 | $61,346 | $507 |
| Incruse Ellipta | 108 | $48,041 | $445 |
| Symbicort | 97 | $44,607 | $460 |
| Trelegy Ellipta | 46 | $34,055 | $740 |
| Advair Diskus | 55 | $30,964 | $563 |
| Flovent Hfa | 50 | $19,886 | $398 |
| Spiriva Respimat | 31 | $18,608 | $600 |
| Serevent Diskus | 11 | $11,733 | $1,067 |
| Advair Hfa | 11 | $10,489 | $954 |
| Wixela Inhub | 26 | $7,679 | $295 |
| Dulera | 13 | $6,880 | $529 |
| Arnuity Ellipta | 28 | $6,587 | $235 |
| Stiolto Respimat | 14 | $5,505 | $393 |
| Ventolin Hfa | 60 | $5,109 | $85 |
| Proair Hfa | 32 | $3,195 | $100 |
| Albuterol Sulfate Hfa | 37 | $2,163 | $58 |
| Montelukast | 82 | $999 | $12 |
| Azelastine | 20 | $989 | $49 |
| Ipratropium | 13 | $709 | $55 |
| Fluticasone Propionate | 45 | $607 | $13 |
| Prednisone | 103 | $538 | $5 |
| Omeprazole | 22 | $288 | $13 |
| Azithromycin | 24 | $209 | $9 |
| Nystatin | 11 | $205 | $19 |
| Ranitidine | 14 | $131 | $9 |
2018: 25 drugs
| Ofev | 15 | $139,624 | $9,308 |
| Spiriva | 198 | $106,735 | $539 |
| Breo Ellipta | 252 | $102,718 | $408 |
| Anoro Ellipta | 120 | $62,940 | $525 |
| Symbicort | 121 | $53,420 | $441 |
| Incruse Ellipta | 113 | $43,834 | $388 |
| Advair Diskus | 72 | $41,326 | $574 |
| Flovent Hfa | 37 | $15,203 | $411 |
| Advair Hfa | 14 | $11,916 | $851 |
| Arnuity Ellipta | 40 | $9,952 | $249 |
| Dulera | 15 | $9,169 | $611 |
| Serevent Diskus | 20 | $7,944 | $397 |
| Combivent Respimat | 14 | $5,340 | $381 |
| Spiriva Respimat | 12 | $4,994 | $416 |
| Ventolin Hfa | 59 | $3,750 | $64 |
| Proair Hfa | 50 | $3,667 | $73 |
| Montelukast | 62 | $671 | $11 |
| Fluticasone Propionate | 60 | $670 | $11 |
| Azelastine | 19 | $639 | $34 |
| Prednisone | 97 | $423 | $4 |
| Ipratropium | 13 | $397 | $31 |
| Omeprazole | 30 | $260 | $9 |
| Ranitidine | 16 | $167 | $10 |
| Bupropion Hcl Sr | 11 | $112 | $10 |
| Azithromycin | 19 | $102 | $5 |
2017: 24 drugs
| Spiriva | 236 | $122,174 | $518 |
| Breo Ellipta | 197 | $76,869 | $390 |
| Anoro Ellipta | 106 | $43,941 | $415 |
| Symbicort | 101 | $42,728 | $423 |
| Advair Diskus | 57 | $30,687 | $538 |
| Incruse Ellipta | 69 | $27,414 | $397 |
| Advair Hfa | 18 | $14,983 | $832 |
| Spiriva Respimat | 29 | $13,380 | $461 |
| Flovent Hfa | 23 | $10,036 | $436 |
| Serevent Diskus | 19 | $7,687 | $405 |
| Dulera | 19 | $5,973 | $314 |
| Proair Hfa | 83 | $5,602 | $67 |
| Arnuity Ellipta | 33 | $5,398 | $164 |
| Ventolin Hfa | 37 | $2,627 | $71 |
| Fluticasone Propionate | 56 | $717 | $13 |
| Montelukast | 46 | $635 | $14 |
| Azelastine | 16 | $480 | $30 |
| Ipratropium | 14 | $469 | $34 |
| Prednisone | 97 | $435 | $4 |
| Levofloxacin | 17 | $311 | $18 |
| Omeprazole | 26 | $298 | $11 |
| Nystatin | 11 | $222 | $20 |
| Azithromycin | 21 | $129 | $6 |
| Ranitidine | 19 | $91 | $5 |
2016: 21 drugs
| Opsumit | 12 | $94,885 | $7,907 |
| Spiriva | 178 | $84,877 | $477 |
| Symbicort | 97 | $36,897 | $380 |
| Breo Ellipta | 88 | $30,420 | $346 |
| Advair Diskus | 65 | $27,987 | $431 |
| Anoro Ellipta | 58 | $24,689 | $426 |
| Advair Hfa | 17 | $13,467 | $792 |
| Spiriva Respimat | 31 | $11,713 | $378 |
| Flovent Hfa | 34 | $10,307 | $303 |
| Proair Hfa | 90 | $6,730 | $75 |
| Incruse Ellipta | 17 | $4,772 | $281 |
| Serevent Diskus | 11 | $3,575 | $325 |
| Ventolin Hfa | 35 | $2,322 | $66 |
| Montelukast | 46 | $1,031 | $22 |
| Azelastine | 18 | $707 | $39 |
| Fluticasone Propionate | 37 | $581 | $16 |
| Prednisone | 99 | $532 | $5 |
| Doxycycline Hyclate | 11 | $353 | $32 |
| Ipratropium | 12 | $213 | $18 |
| Azithromycin | 11 | $100 | $9 |
| Sulfamethoxazole-Trimethoprim | 14 | $78 | $6 |
2015: 23 drugs
| Spiriva | 200 | $90,027 | $450 |
| Symbicort | 125 | $48,135 | $385 |
| Advair Diskus | 106 | $39,732 | $375 |
| Anoro Ellipta | 50 | $19,418 | $388 |
| Advair Hfa | 29 | $18,828 | $649 |
| Flovent Hfa | 42 | $10,121 | $241 |
| Breo Ellipta | 27 | $8,262 | $306 |
| Proair Hfa | 98 | $6,927 | $71 |
| Foradil | 24 | $5,368 | $224 |
| Combivent Respimat | 15 | $4,324 | $288 |
| Dulera | 13 | $3,396 | $261 |
| Ventolin Hfa | 18 | $1,361 | $76 |
| Montelukast | 57 | $1,200 | $21 |
| Ipratropium | 28 | $754 | $27 |
| Fluticasone Propionate | 55 | $722 | $13 |
| Xopenex Hfa | 12 | $703 | $59 |
| Mycophenolate Mofetil | 17 | $698 | $41 |
| Prednisone | 122 | $666 | $5 |
| Levofloxacin | 13 | $404 | $31 |
| Omeprazole | 24 | $302 | $13 |
| Nystatin | 17 | $278 | $16 |
| Sulfamethoxazole-Trimethoprim | 19 | $68 | $4 |
| Azithromycin | 14 | $59 | $4 |
2014: 18 drugs
| Tracleer | 12 | $93,403 | $7,784 |
| Spiriva | 184 | $74,970 | $407 |
| Advair Diskus | 141 | $57,818 | $410 |
| Symbicort | 118 | $34,510 | $292 |
| Advair Hfa | 29 | $14,682 | $506 |
| Combivent Respimat | 43 | $11,949 | $278 |
| Proair Hfa | 65 | $5,238 | $81 |
| Flovent Hfa | 21 | $4,972 | $237 |
| Qvar | 14 | $2,948 | $211 |
| Foradil | 11 | $2,467 | $224 |
| Fluticasone Propionate | 69 | $1,268 | $18 |
| Xopenex Hfa | 21 | $1,132 | $54 |
| Montelukast | 26 | $795 | $31 |
| Ventolin Hfa | 13 | $581 | $45 |
| Prednisone | 71 | $538 | $8 |
| Ipratropium | 15 | $518 | $35 |
| Omeprazole | 25 | $303 | $12 |
| Azithromycin | 22 | $244 | $11 |
2013: 21 drugs
| Tracleer | 11 | $76,788 | $6,981 |
| Advair Diskus | 175 | $68,922 | $394 |
| Spiriva | 186 | $66,432 | $357 |
| Symbicort | 99 | $28,026 | $283 |
| Advair Hfa | 64 | $22,455 | $351 |
| Flovent Hfa | 33 | $7,869 | $238 |
| Combivent Respimat | 27 | $7,006 | $259 |
| Qvar | 25 | $4,188 | $168 |
| Proair Hfa | 55 | $3,659 | $67 |
| Combivent | 13 | $2,934 | $226 |
| Serevent Diskus | 12 | $2,362 | $197 |
| Fluticasone Propionate | 58 | $1,409 | $24 |
| Ventolin Hfa | 21 | $1,084 | $52 |
| Montelukast | 22 | $782 | $36 |
| Azithromycin | 31 | $737 | $24 |
| Omeprazole | 36 | $608 | $17 |
| Prednisone | 62 | $275 | $4 |
| Ciprofloxacin | 11 | $213 | $19 |
| Ranitidine | 11 | $98 | $9 |
| Sulfamethoxazole-Trimethoprim | 17 | $84 | $5 |
| Furosemide | 18 | $76 | $4 |
Money from drug and device companies
$563 in 2025
| 2025 | 8 | 24 | None | $563 |
| 2024 | 5 | 9 | None | $180 |
| 2020 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $160 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $121 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jascayd | $98 | 4 payments
|
| Verona Pharma | Ohtuvayre | $49 | 2 payments
|
| Genzyme | Dupixent | $41 | 2 payments
|
| Electromed | Smartvest | $39 | 4 payments
|
See all 24 published payments
| Verona Pharma | Meals · 2025-12-09 | Ohtuvayre | $14 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-08 | Jascayd | $28 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-02 | Jascayd | $15 |
| Electromed | Meals · 2025-12-02 | Smartvest | $4 |
| Electromed | Meals · 2025-12-02 | Smartvest | $14 |
| Electromed | Meals · 2025-12-02 | Smartvest | $4 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-11-14 | Jascayd | $31 |
| GlaxoSmithKline | Meals · 2025-11-06 | Nucala | $32 |
| Verona Pharma | Meals · 2025-11-04 | Ohtuvayre | $35 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-29 | Breztri | $33 |
| Electromed | Meals · 2025-10-20 | Smartvest | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-11 | Tezspire | $30 |
| GlaxoSmithKline | Meals · 2025-10-06 | Nucala | $27 |
| Insmed | Meals · 2025-09-23 | Arikayce | $18 |
| Baxter Healthcare | Meals · 2025-09-09 | Hillrom - Volara System | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-02 | Breztri | $31 |
| GlaxoSmithKline | Meals · 2025-08-18 | Nucala | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-29 | Tezspire | $27 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-23 | Ofev | $24 |
| Genzyme | Meals · 2025-07-22 | Dupixent | $17 |
| GlaxoSmithKline | Meals · 2025-07-11 | Nucala | $26 |
| GlaxoSmithKline | Meals · 2025-05-08 | Nucala | $26 |
| Genzyme | Meals · 2025-02-14 | Dupixent | $23 |
| GlaxoSmithKline | Meals · 2025-01-17 | Nucala | $17 |
See earlier years (2024, 2020)
2024: $180
| Boehringer Ingelheim Pharmaceuticals | Ofev | $78 | 3 payments
|
| Amgen | Tezspire | $33 | 1 payment
|
| Genzyme | Dupixent | $26 | 1 payment
|
| Philips North America | (8874) Incourage | $24 | 1 payment
|
| GlaxoSmithKline | Nucala | $20 | 1 payment
|
2020: $14
| Boehringer Ingelheim Pharmaceuticals | Spiriva Respimat | $14 | 1 payment
|
Professional record
- NPI
- 1063608719
- Licence
- CA A92908California A92908: Current · expires 2027-08-31
- Group
- Physician Services at El Camino Hospital · Sutter Bay Medical Foundation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X)
- Mailing address
- 2350 W. El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2007-09-17
- NPI last updated
- 2017-09-05
This is when the NPI record was last certified, not a medical board exam.